PMID- 38319223
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 2766-5526 (Electronic)
IS  - 2766-5526 (Linking)
VI  - 1
IP  - 4
DP  - 2022 Apr
TI  - Precision Diagnostics for Type 2 Diabetes Mellitus - Have We Arrived?
PG  - EVIDe2200039
LID - 10.1056/EVIDe2200039 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is defined by a common end point: hyperglycemia 
      diagnosed by fasting plasma glucose, plasma glucose during an oral glucose 
      tolerance test, or hemoglobin A1c without autoimmune beta-cell destruction.(1) 
      Historically, little attention has been paid to the etiologies driving 
      hyperglycemia; as a result, there has been an absence of an elegant 
      pathophysiologically directed diagnostic and therapeutic approach. T2DM has 
      simply been thought to be a result of insulin deficiency and/or peripheral 
      insulin resistance. However, the phenotype of T2DM is heterogeneous, as is the 
      pathophysiology.(2,3).
FAU - Colling, Caitlin
AU  - Colling C
AD  - Massachusetts General Hospital, Boston.
FAU - Rosen, Clifford J
AU  - Rosen CJ
AD  - Maine Medical Center Research Institute, Scarborough, ME.
LA  - eng
PT  - Editorial
DEP - 20220322
PL  - United States
TA  - NEJM Evid
JT  - NEJM evidence
JID - 9918317485806676
SB  - IM
EDAT- 2022/04/01 00:00
MHDA- 2022/04/01 00:01
CRDT- 2024/02/06 10:14
PHST- 2022/04/01 00:01 [medline]
PHST- 2022/04/01 00:00 [pubmed]
PHST- 2024/02/06 10:14 [entrez]
AID - 10.1056/EVIDe2200039 [doi]
PST - ppublish
SO  - NEJM Evid. 2022 Apr;1(4):EVIDe2200039. doi: 10.1056/EVIDe2200039. Epub 2022 Mar 
      22.